Related Experiment Video
Updated: May 6, 2026
05:51
Intracerebroventricular and Intravascular Injection of Viral Particles and Fluorescent Microbeads into the Neonatal Brain
Published on: July 24, 2016
19.1K
Kawasaki disease in infants
Jung Sook Yeom1, Hyang Ok Woo, Ji Sook Park
1Department of Pediatrics, Gyeongsang Institute of Health Science, Gyeongsang National University School of Medicine, Jinju, Korea.
Korean Journal of Pediatrics
|November 14, 2013
Summary
Diagnosing Kawasaki disease (KD) in infants is challenging due to incomplete symptoms, increasing the risk of heart complications. Early suspicion and evaluation are crucial for timely intervention in pediatric cardiology.
Area of Science:
- Pediatrics
- Cardiology
- Infectious Diseases
Background:
- Kawasaki disease (KD) is a leading cause of acquired heart disease in children.
- Diagnosis relies on clinical signs, posing challenges for incomplete or atypical presentations, particularly in infants.
- Infantile KD is associated with a higher risk of coronary artery abnormalities.
Purpose of the Study:
- To highlight the diagnostic difficulties of Kawasaki disease in infants under one year old.
- To emphasize the link between incomplete KD manifestations and coronary artery issues.
- To underscore the necessity of early suspicion and prompt evaluation for infantile KD.
Main Methods:
- This study is a review of existing literature on Kawasaki disease diagnosis in infants.
- Analysis focuses on clinical criteria and diagnostic challenges in the pediatric population.
- Coronary artery abnormality development in relation to incomplete KD is examined.
Main Results:
- Incomplete Kawasaki disease presentations are common in infants under one year.
- Delayed or missed diagnosis in this age group correlates with increased incidence of coronary artery abnormalities.
- Clinical manifestations can be subtle and difficult to identify in very young children.
Conclusions:
- Early suspicion and thorough evaluation are critical for managing Kawasaki disease in infants.
- Prompt diagnosis and treatment can mitigate the risk of severe cardiac complications.
- Further research into diagnostic markers for infantile KD is warranted.
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
413
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
413
01:25Immunodeficiency Diseases
3.8K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
3.8K
01:29Drug Dosing: Infants and Children
1.0K
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
414
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
414
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
975
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
975
01:20Inborn Errors of Metabolism
1.1K
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
1.1K